Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 373,590,880
  • Shares Outstanding, K 2,407,623
  • Annual Sales, $ 85,159 M
  • Annual Income, $ 35,153 M
  • EBIT $ 13,952 M
  • EBITDA $ 21,438 M
  • 60-Month Beta 0.53
  • Price/Sales 4.40
  • Price/Cash Flow 11.38
  • Price/Book 5.34

Options Overview Details

View History
  • Implied Volatility 14.88% ( +0.07%)
  • Historical Volatility 14.34%
  • IV Percentile 24%
  • IV Rank 23.57%
  • IV High 22.48% on 08/05/24
  • IV Low 12.53% on 05/09/24
  • Put/Call Vol Ratio 0.33
  • Today's Volume 23,402
  • Volume Avg (30-Day) 24,160
  • Put/Call OI Ratio 0.70
  • Today's Open Interest 355,042
  • Open Int (30-Day) 349,657

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 1.99
  • Number of Estimates 7
  • High Estimate 2.10
  • Low Estimate 1.94
  • Prior Year 2.29
  • Growth Rate Est. (year over year) -13.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
150.76 +2.93%
on 11/14/24
166.00 -6.52%
on 10/23/24
-8.28 (-5.07%)
since 10/22/24
3-Month
150.76 +2.93%
on 11/14/24
168.85 -8.10%
on 09/04/24
-7.18 (-4.42%)
since 08/22/24
52-Week
143.13 +8.41%
on 04/18/24
168.85 -8.10%
on 09/04/24
+4.35 (+2.88%)
since 11/22/23

Most Recent Stories

More News
3 Dividend Stocks That Are Screaming Buys in November

Political uncertainty has created buying opportunities among blue-chip healthcare stocks with big-time dividends.

JNJ : 155.17 (-0.21%)
ABBV : 176.95 (+3.04%)
PFE : 25.65 (+2.07%)
2 Unstoppable Dividend Stocks to Buy Now With $500

Whether you prefer growth stocks, value stocks, dividend stocks, or a mixture of investments in your portfolio, price should only be one factor you consider when determining which businesses to add.

JNJ : 155.17 (-0.21%)
UPS : 134.82 (+2.63%)
2 Dow Jones Dividend Stocks With Yields Above 3% You Can Buy Now and Hold at Least a Decade

If you have any faith in economic indicators, right now seems like a terrible time to buy stocks. A long bull market has pushed the major market indices up to record highs.

KO : 63.92 (+0.25%)
JNJ : 155.17 (-0.21%)
Pharma Stock Roundup: EU Nod for PFE's Hympavzi, NVS Ups Sales View

This week Novartis NVS upgraded its mid-term sales growth guidance. The European Commission approved Pfizer’s PFE hemophilia drug Hympavzi (marstacimab). AstraZeneca’s AZN Tagrisso was recommended...

AZN : 65.63 (+2.13%)
JNJ : 155.17 (-0.21%)
LLY : 748.01 (-0.25%)
NVS : 104.28 (+0.41%)
PFE : 25.65 (+2.07%)
Health Canada Authorizes CARVYKTI® (ciltacabtagene autoleucel) for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy

/CNW/ - Johnson & Johnson (NYSE: JNJ) announced today that Health Canada has issued a Notice of Compliance (NOC) for CARVYKTI® (ciltacabtagene autoleucel) for...

JNJ : 155.17 (-0.21%)
J&J Loses Around $24B in a Month: How to Play the Stock?

J&J JNJ stock has plunged 6.1% in a month, losing almost $24 billion of its market value.Though slowing sales in its MedTech segment, the upcoming patent expiration of its blockbuster drug, Stelara, and...

NVO : 105.06 (+2.37%)
JNJ : 155.17 (-0.21%)
LLY : 748.01 (-0.25%)
KVUE : 24.08 (-0.04%)
Is MicroStrategy Stock Still a Buy at New Highs for Its Massive Bitcoin Hoard?

MicroStrategy stock has gained close to 3,000% since the company started holding Bitcoin on its balance sheet more than four years ago.

MSTR : 421.88 (+6.19%)
NVDA : 141.95 (-3.22%)
IBM : 222.97 (+0.26%)
JNJ : 155.17 (-0.21%)
NKE : 77.40 (+3.06%)
^BTCUSD : 97,866.59 (-1.41%)
ORIC: Working with Two Pharma Giants, Analysts See +100% Upside

ORIC Pharmaceuticals is a stock analyst price targets currently signal double-bagger potential in. See what the excitement around this firm is all about.

BAYRY : 5.1500 (+1.18%)
JNJ : 155.17 (-0.21%)
ORIC : 9.59 (+5.15%)
PFE : 25.65 (+2.07%)
3 Oversold Dividend Aristocrats Ready To Explode in 2025

These three companies all have one thing in common: they are all on sale.

KO : 63.92 (+0.25%)
JNJ : 155.17 (-0.21%)
ABBV : 176.95 (+3.04%)
Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline Setback

The third-quarter earnings season came to an end this week for large drugmakers, with AstraZeneca AZN and Bayer BAYRY announcing their results. AbbVie’s ABBV schizophrenia candidate, added from a recent...

BAYRY : 5.1500 (+1.18%)
AZN : 65.63 (+2.13%)
JNJ : 155.17 (-0.21%)
MRK : 99.18 (-0.68%)
ABBV : 176.95 (+3.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 159.83
2nd Resistance Point 158.47
1st Resistance Point 156.82
Last Price 155.17
1st Support Level 153.82
2nd Support Level 152.46
3rd Support Level 150.81

See More

52-Week High 168.85
Fibonacci 61.8% 159.02
Fibonacci 50% 155.99
Last Price 155.17
Fibonacci 38.2% 152.96
52-Week Low 143.13

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar